Based on the results of the Pamoja Tulinde Maisha (PALM) trial (1), mAb114 (ansuvimab; a single human monoclonal antibody [mAb] that binds to the EBOV glycoprotein [GP1,2]) and REGN-EB3 (atoltivimab, maftivimab, and odesivimab; mouse-derived then humanized mAbs that target different epitopes of EBOV GP1,2) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of Ebola virus disease (EVD) (2, 3). Here, GTPBP1 is linked to Ebola hemorrhagic fever.